New hep c combo shows early promise in small safety trial
NCT ID NCT00630058
First seen Jan 09, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This early-phase study tested a new drug called MP-424 alongside standard hepatitis C treatments (peginterferon alfa-2b and ribavirin) in 20 adults with genotype 1b chronic hepatitis C. The main goal was to check the drug's safety and how it moves through the body. Researchers also measured how well it lowered hepatitis C virus levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
Explore the condition pages connected to this study.